🟢 Connect Biopharma is trading 6% up in pre-market despite no new company-specific catalyst

Connect Biopharma is trading 6.31% up at $2.34, with no new company-specific catalyst identified for September 1, 2026.

• The latest material update remains the August 12 second-quarter report, which said enrollment was complete in both Phase 2 Seabreeze STAT studies.
• Topline results are expected in September 2026, with asthma data anticipated in early September, potentially contributing to investor interest but not confirmed as the direct cause.